• / Free eNewsletters & Magazine
  • / My Account
Home>Search Results

Related Content

  1. Videos
  2. Articles
  1. Pfizer Shares Still Attractive

    A new CEO, a $5 billion share-repurchase program, and a handful of promising new drugs make Pfizer shares look cheap even after today's runup, according to Morningstar's Damien Conover.

  2. Significant Upside for Pharma Stock Prices, Dividends

    Pharmaceutical firms' adept handling of patent expirations has boosted investors' opinions of the sector, says Morningstar's Damien Conover.

  3. Even After Patent Cliff, Pfizer Is Undervalued

    A new ROIC-focused process for compound development plus the value of Pfizer's other businesses add up to a fair value well in excess of $14, says RS Investments manager Joe Wolf.

  4. Better Days Ahead for Pharma Firms

    Valuations for pharmaceutical companies should rebound once investors look past today's patent expirations to tomorrow's new drugs, says Morningstar's Damien Conover.

  1. Emerging Nations: A Blossoming Field For Drug and Medical-Device Firms

     

  2. Pfizer Inc. PFE Q3 2010 Earnings Call Transcript

    Good day everyone, and welcome to Pfizer s Third Quarter 2010 Earnings Conference Call. Today s call is being recorded.

  3. Financial Planning for Athletes: 6 Rules for Success

    Working with sports stars can be prestigious, even glamorous -- and is often a highly sought after market niche for financial advisors and wealth managers, but professional athletes can also present advisors with a minefield of challenges

  4. Dogs of the Dow’s ‘Mutts’ Have No Bite

     

1
ShareEmail
Print
Text Size
Comment
blog comments powered by Disqus
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.